Is HCA (HCA) Using Index Removal To Quietly Redefine Its Growth and Capital Allocation Playbook?
HCA Healthcare (HCA) was recently removed from several Russell growth indexes, a reclassification reflecting its investment style rather than operational changes. Concurrently, HCA is investing US$5.5–US$6.0 billion into expanding hospital and emergency capacity and advancing gene-editing research. This article explores how these developments could reshape HCA's investment profile, focusing on large-scale growth projects and complex clinical care capabilities.
Can HCA's Capacity Expansion Strategy Fuel Its Long-Term Growth?
HCA Healthcare is significantly investing in expanding its healthcare network, with a focus on increasing hospital beds, emergency room capacity, and acquiring outpatient healthcare assets. This strategy aims to meet future demand, despite recent short-term volume pressures, and has led to a strong investment pipeline. Peers like Tenet Healthcare and Universal Health Services are also pursuing similar expansion strategies to capitalize on the growing demand for healthcare services.
Cantor Fitzgerald lowers HCA Healthcare price target to $528 on setup
Cantor Fitzgerald has lowered its price target for HCA Healthcare (NYSE:HCA) to $528 from $588, citing a challenging outlook for healthcare providers in late 2026 and 2027, although maintaining an "Overweight" rating. Despite the lowered target, the stock is currently trading significantly below this new target at $417.07, and InvestingPro analysis suggests it is undervalued with "GREAT" financial health. The firm believes HCA and THC have strong potential to meet guidance expectations due to the impact of the Florida DPP.
How HCA Healthcare’s (HCA) Advanced Therapy Research Highlights Its High-Acuity Care Capabilities
HCA Healthcare (NYSE:HCA) is highlighted for its advanced therapy research, particularly in gene-editing for sickle cell disease, showcasing its capabilities in high-acuity care. This research, published in The New England Journal of Medicine, underscores the specialized services large hospital systems like HCA can provide, differentiating them through service depth, scale, and clinical infrastructure. While not a biotech stock, HCA's involvement in such advanced medical fields demonstrates its competitive edge in the healthcare industry.
How HCA Healthcare’s (HCA) Advanced Therapy Research Highlights Its High-Acuity Care Capabilities
HCA Healthcare (NYSE:HCA) is recognized as a top medical care facility stock, with analysts projecting a significant upside. The company's recent research published in The New England Journal of Medicine, focusing on gene-editing therapy for sickle cell disease and beta thalassemia, underscores its high-acuity care capabilities. This highlights the crucial role of large hospital systems in advanced medical care and their competition based on service depth, scale, and clinical infrastructure.
HCA West Florida names new CEOs for Northside, Brandon hospitals
HCA West Florida has appointed new CEOs for its Northside and Brandon hospitals. These appointments place experienced HCA leaders in charge of facilities serving Hillsborough and Pinellas counties. The article specifically names Steve Young as the new CEO of HCA Florida Brandon Hospital.
HCA Healthcare Inc. stock outperforms competitors on strong trading day
Shares of HCA Healthcare Inc. (HCA) increased by 1.60% to $417.07 on Monday, marking its third consecutive day of gains. The stock's performance outpaced the broader market, with the S&P 500 Index (SPX) rising 0.72% and the Dow Jones Industrial Average (DJIA) rising 0.29% on an overall positive trading day.
If EPS Growth Is Important To You, HCA Healthcare (NYSE:HCA) Presents An Opportunity
This article highlights HCA Healthcare (NYSE:HCA) as an attractive investment opportunity due to its consistent earnings per share (EPS) growth. Over the last five years, HCA has demonstrated an average annual EPS increase of 15%, driven by revenue growth and share repurchases. While its P/E ratio is currently higher than the industry average, its continued profitability and growth trajectory are presented as reasons for investor consideration.
FDA deepens Vertex's Casgevy label, opening treatment for patients as young as 2
The FDA has expanded the label for Vertex's gene therapy Casgevy, co-developed with CRISPR Therapeutics, to include patients as young as two years old for sickle cell disease and beta thalassemia. This expansion opens treatment to an additional 5,500 children in the U.S., offering earlier intervention to prevent cumulative organ damage. The decision is supported by positive results from ongoing phase 3 trials in pediatric populations.
HCA Healthcare, Inc. (HCA) Stock Analysis: A Robust 21.87% Upside Potential Awaits Investors
HCA Healthcare (NYSE: HCA) is presented as an attractive investment in the healthcare sector, boasting a $91.07 billion market capitalization and a network of medical facilities. Analysts have set an average target price of $500.29, indicating a potential upside of 21.87% from its current price of $410.5. Despite some bearish technical indicators, the company's strong financial performance, including a robust revenue growth rate of 4.30% and an impressive EPS of 29.02, combined with a sustainable dividend yield, positions it as a promising opportunity for growth and income-focused investors.
ADUS - Addus HomeCare Corp Options
This article provides a detailed financial overview of Addus HomeCare Corp (ADUS), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists performance metrics such as EPS growth, sales growth, insider/institutional ownership, profitability, and stock performance over different periods.
THC - Tenet Healthcare Corp Latest SEC Filings
This article provides a detailed financial overview of Tenet Healthcare Corp (THC), including key financial metrics, stock performance data, and insider/institutional ownership percentages. It highlights the company's market capitalization, revenue, earnings per share, and various valuation ratios, alongside recent stock performance across different timeframes. The content appears to be a snapshot of financial data and not a news article.
TOI - Oncology Institute Inc Options
This article provides a comprehensive overview of Oncology Institute Inc. (TOI) stock, detailing its financial performance, key ratios, ownership data, and stock performance metrics. It covers important financial figures like market cap, income, sales, and various P/E and EV ratios, alongside insider and institutional ownership percentages. The report also highlights the stock's price changes, volatility, and performance across different timeframes.
10 Best Medical Care Facilities Stocks to Buy According to Analysts
This article identifies RadNet, Inc. (NASDAQ:RDNT) as one of the top medical care facilities stocks, highlighting its focus on outpatient diagnostic facilities and recent technological advancements, such as the launch of Reporting Pro by its subsidiary DeepHealth. Analysts project a 30.6% average upside for RadNet. The company's push into digital health positions it as more than a traditional imaging operator, aiming to scale its care model.
10 Best Medical Care Facilities Stocks to Buy According to Analysts
This article identifies 10 best medical care facilities stocks based on analyst recommendations. It highlights Option Care Health, Inc. (NASDAQ:OPCH) as one of the top choices, noting its significant upside potential according to analysts. The company's recent ranking on TIME's World's Most Impactful Companies 2026 list and its focus on home and alternate-site infusion care are presented as key indicators of its strong operating model and relevance in the evolving healthcare landscape.
CON - Concentra Group Holdings Parent Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Concentra Group Holdings Parent Inc (CON). It covers various financial metrics, stock performance indicators, insider and institutional ownership, and analyst recommendations, offering a detailed snapshot of the company's current market position.
If You Invested $1,000 in Hca Healthcare Inc (HCA)
This article analyzes the historical performance of HCA Healthcare Inc. (HCA) stock, demonstrating the returns on a $1,000 investment over various periods (1, 5, and 10 years). It details the company's annual stock performance against the S&P 500 and provides an overview of HCA Healthcare, including its business focus, initiatives in clinical research, community engagement, and workforce development. The report highlights HCA's role as a learning health system and its robust operational network across the U.S. and UK.
SY - So-Young International Inc ADR Latest SEC Filings
This article provides detailed financial information and performance metrics for So-Young International Inc. (SY). It includes the latest stock price, key financial ratios, insider and institutional ownership data, analyst recommendations, and various performance indicators over different periods. The filing highlights the company's status in the healthcare information services sector in China.
Fideuram Intesa Sanpaolo Private Banking S.P.A. Trims Stock Position in HCA Healthcare, Inc. $HCA
Fideuram Intesa Sanpaolo Private Banking S.P.A. reduced its stake in HCA Healthcare, Inc. by 23.6% in the first quarter, selling 2,778 shares and holding 8,999 shares valued at $4,259,000. Despite this, other institutional investors have increased their positions in HCA Healthcare, and the company has an average "Moderate Buy" rating from analysts with an average price target of $503.00. The article also details HCA Healthcare's recent financial performance, including Q1 earnings, revenue, and dividend announcement.
ENSG - Ensign Group Inc Options
This page provides a detailed financial overview of Ensign Group Inc (ENSG) as of July 2, 2026. It includes key financial metrics, stock performance data, basic company information, and analyst recommendations. The data covers various aspects such as market capitalization, earnings, sales, dividends, insider and institutional ownership, and profitability ratios.
Surgery Partners (SGRY) Drew Fresh Optimism, Is It Still Only 4% Undervalued?
Surgery Partners (SGRY) saw its stock rise by 2.7% after positive commentary from Cantor Fitzgerald, which projected profitability and net income growth despite recent soft operating trends. Although the stock has seen significant short-term gains, its one-year return is still down 22.2%, with analysts currently pegging its fair value at $17.95, closely aligning with its last close price of $17.23. The company faces pressures from rising interest expenses and slower acquisitions, which could impact its margin repair narrative.
SGRY - Surgery Partners Inc Latest SEC Filings
This article provides a detailed financial overview of Surgery Partners Inc (SGRY), including its latest stock performance, key financial metrics, valuation ratios, and ownership details. It highlights the company's recent stock close, percentage change, and various profitability and efficiency ratios. The data also covers analyst recommendations and price targets, offering a comprehensive snapshot of SGRY's market position.
HCA Florida Healthcare trauma surgeon discusses award-winning trauma center
Dr. Cathy Ho, a trauma surgeon at HCA Florida Fort Walton-Destin Hospital, discusses the award-winning trauma center in a video. HCA Florida Healthcare is one of the largest healthcare networks in the state, comprising four hospitals and eight freestanding emergency rooms in the Panhandle, providing expert medical care across numerous locations. The article highlights the critical role of trauma centers in addressing traumatic injuries that can be fatal or permanently disabling.
CON - Concentra Group Holdings Parent Inc Short Interest
This article provides a detailed financial overview of Concentra Group Holdings Parent Inc (CON), including its short interest, key financial metrics, performance indicators, and analyst recommendations. It highlights the company's recent stock performance, insider and institutional ownership, and profitability margins, presenting a comprehensive snapshot for potential investors.
Elevation Point Wealth Partners LLC Has $10.03 Million Stock Position in HCA Healthcare, Inc. $HCA
Elevation Point Wealth Partners LLC significantly increased its stake in HCA Healthcare, boosting its holdings by 217.8% to 21,202 shares, now valued at approximately $10.03 million. Despite HCA Healthcare missing profit expectations but beating revenue estimates in its latest earnings report, Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $503. The company also declared a quarterly dividend of $0.78 per share.
A Look at HCA Healthcare Inc (HCA) After 4.4% Gain -- GF Value $452.20 vs Price $410.50
HCA Healthcare Inc (HCA) shares rose 4.4% to $410.50, and GuruFocus's GF Value™ suggests it is 9.2% undervalued at $452.20, earning a strong GF Score™ of 91/100. Despite high profitability and growth scores, the company shows lower financial strength and momentum. There have been no insider transactions in the last three months, indicating a neutral sentiment among insiders regarding immediate stock performance changes.
Tenet Healthcare Jumps 5.7% Amid Sector-Wide Rally
Tenet Healthcare Corporation saw its stock surge 5.7% to $202.03, participating in a broader sector-wide rally that also benefited peers like HCA and UHS. This movement appears to be driven by shifting investor sentiment towards hospital operators, possibly due to improving fundamentals, rather than any company-specific news. The strong performance, with significant trading volume, suggests renewed investor confidence in the healthcare facilities market.
HCA Healthcare Foundation awards grants to 89 Middle Tennessee nonprofits, advancing community health
The HCA Healthcare Foundation has awarded $2.1 million in grants to 89 nonprofit organizations across Middle Tennessee. These grants aim to strengthen community health by supporting groups that address various needs such as access to care, food insecurity, housing, education, and services for vulnerable populations. The initiative underscores HCA Healthcare's commitment, through its TriStar Health division, to improving local well-being beyond hospital walls.
HCA Healthcare Jumps 5.2% Amid Sector-Wide Rally
HCA Healthcare experienced a 5.2% surge, reaching $413.77 per share, as a broad rally lifted hospital operators. This sector-wide momentum also benefited peers like Tenet Healthcare, Universal Health Services, and Encompass Health, indicating institutional investor interest despite no specific news catalyst. HCA's significant market cap and leadership suggest its performance is a key indicator for the healthcare facilities sector.
HCA Healthcare Inc. stock underperforms Thursday when compared to competitors despite daily gains
HCA Healthcare Inc. (HCA) stock increased by 4.39% to $410.50 on Thursday, despite an overall mixed trading session for the market. The S&P 500 Index remained largely unchanged, while the Dow Jones Industrial Average saw a 1.14% rise. This marks the second consecutive day of gains for HCA.
HCA Healthcare Jumps 5.2% Amid Sector-Wide Rally
HCA Healthcare saw a 5.2% increase in its stock price, reaching $413.77 per share, as part of a broad sector-wide rally affecting hospital operators. This synchronized advance, also seen in peers like Tenet Healthcare, Universal Health Services, and Encompass Health, suggests a rotation of investor capital into healthcare facilities despite the absence of specific news catalysts. The rally adds to HCA's 2026 performance, with its significant market cap and trading volume reflecting heightened investor interest, potentially driven by upcoming earnings season expectations or broader healthcare policy trends.
Tenet Healthcare Jumps 5.7% Amid Sector-Wide Rally
Tenet Healthcare Corporation saw a 5.7% increase, closing at $202.03, as part of a broader rally in the healthcare sector, with other hospital operators like HCA and UHS also experiencing significant gains. This sector-wide movement suggests renewed investor confidence in hospital operators due to possible shifts in reimbursement trends, utilization patterns, or healthcare policy expectations, rather than any company-specific news for Tenet. Investors should monitor if the sector momentum continues and consider upcoming earnings reports for confirmation of improved fundamentals.
HCA Healthcare gains as investors weigh improving physician trends and a possible rebound after prior guidance-driven weakness
HCA Healthcare (HCA) saw a 3.6% increase in its stock price, likely driven by positive analyst reports regarding improving physician staffing trends in the second quarter. This rebound follows earlier pressure on the stock due to reduced 2026 earnings guidance. The article also details recent insider trading activity, primarily sales, and significant institutional investor movements, alongside analyst ratings and price targets for HCA.
Select Medical (NYSE:SEM) leaves NYSE after $3.9B buyout, one-cent deal spread
Select Medical Holdings Corporation (NYSE:SEM) has delisted from the NYSE after a $3.9 billion cash buyout, with its shares last trading at $16.51, just one cent above the $16.50 per share offer. The merger, led by Executive Chairman Robert A. Ortenzio and other partners, closed on July 1st, leading to SEM's removal from the S&P SmallCap 600. Goldman Sachs & Co. LLC advised that the $16.50 cash offer was fair to shareholders, while the company maintained its 2026 guidance prior to the deal.
Does Acadia Healthcare (ACHC) Joining the Russell 2000 Reframe Its Behavioral Health Investment Narrative?
Acadia Healthcare (ACHC) was moved from the Russell 1000 to the Russell 2000 Index, recategorizing it into the small-cap value universe. This technical shift could affect its investor base and liquidity but doesn't fundamentally change its near-term financials. Key factors for its investment narrative remain execution on facility performance, leadership by CEO Debra Osteen, and managing risks associated with Medicaid reimbursement policies, rather than the index change itself.
HCA - HCA Healthcare Inc Options
This article provides a detailed financial snapshot of HCA Healthcare Inc. (HCA), including its latest stock performance, key financial metrics, valuation ratios, and ownership data. It covers various performance indicators like EPS, sales growth, insider and institutional ownership, and long-term stock performance, alongside analyst recommendations.
HCA Healthcare Earnings Preview: What to Expect
HCA Healthcare (HCA) is poised to release its Q2 earnings, with analysts projecting a diluted EPS of $7.37, a 7.8% increase year-over-year. Despite the stock underperforming the S&P 500 and the healthcare sector ETF over the past year, strong fundamentals, rising patient volumes, and analyst optimism point to potential upside. Analysts rate HCA a "Moderate Buy" with an average price target implying a 25.4% increase.
Cantor Fitzgerald reiterates HCA Healthcare stock rating on physician staffing
Cantor Fitzgerald has reiterated its "Overweight" rating and $588.00 price target for HCA Healthcare (NYSE:HCA), citing improvements in physician staffing data for the second quarter of 2026 compared to its peers. While HCA experienced bonus increases similar to other companies, it was the only one successful in using these to close staffing gaps. The report also highlighted that HCA's stock appears undervalued based on InvestingPro analysis, despite some worsening inpatient psychiatric trends in certain markets and leadership changes announced by the company.
ADUS - Addus HomeCare Corp Forecast, Target Price
This article provides a detailed financial overview and forecast for Addus HomeCare Corp (ADUS) as of July 2nd. It includes key financial metrics such as market cap, income, sales, price-to-earnings ratios, and growth rates. The data also covers insider and institutional ownership, profitability, stock performance, and analyst recommendations with a target price.
HCA - HCA Healthcare Inc Volatility & Greeks
This article provides a detailed financial overview of HCA Healthcare Inc (HCA), including its stock performance, key financial metrics, volatility, and various valuation ratios. It covers aspects like market capitalization, income, sales, dividend information, and insider/institutional ownership, offering a snapshot of the company's current financial health and market position.
Beyond the Hospital Walls: Why USPI Is Becoming Tenet's Growth Engine
Tenet Healthcare Corporation is seeing its growth increasingly driven by its United Surgical Partners International (USPI) segment, which focuses on ambulatory surgery centers. USPI generated strong first-quarter 2026 results with a 6.1% year-over-year increase in adjusted EBITDA and significant investment in new ASCs. This strategy positions Tenet to capitalize on the ongoing shift towards lower-cost outpatient care, enhancing long-term growth and profitability, similar to peers like Surgery Partners and HCA Healthcare.
HCA Healthcare focuses on hospital operations as investors watch US care demand
HCA Healthcare, a major US hospital operator, is focusing on efficient operations, staffing, and service mix to maintain long-term value amidst fluctuating healthcare demand and costs. Investors are closely monitoring its ability to manage its extensive network of acute-care facilities, balance inpatient and outpatient services, and align clinical quality with financial stability. The company's stock performance is influenced by patient volumes, reimbursement trends, labor costs, and broader macroeconomic conditions affecting the healthcare sector.
HCA Healthcare (HCA) Reports Promising Gene-Editing Therapy Study Results
HCA Healthcare (HCA) has announced promising results from a gene-editing therapy study published in The New England Journal of Medicine. The study evaluated exa-cel for children aged 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia, showing all participants achieved significant positive outcomes. Despite these clinical advancements, TD Cowen analyst Ryan Langston lowered HCA's price target due to flat year-over-year revenue, and the company also announced a key executive transition.
Cantor Fitzgerald reiterates HCA Healthcare stock rating at Overweight
Cantor Fitzgerald has reiterated an "Overweight" rating for HCA Healthcare (NYSE:HCA) with a price target of $588.00, suggesting significant upside from its current price. The firm noted attractive pricing metrics for the hospital operator, despite consensus expectations for a step-down in results. Additionally, the article mentions HCA Healthcare's acquisition of The College of Health Care Professions and recent news regarding executive changes and a gene-editing therapy trial.
VivaScore partners with HCA Healthcare UK to extend the impact of health screening through cutting-edge digital platform
VivaScore has announced a partnership with HCA Healthcare UK to enhance patient engagement with their health between screening appointments. The collaboration integrates VivaScore's digital platform with HCA Healthcare UK's doctor-led screening services, offering patients 12 months of complimentary access to an app that provides data-driven health insights. This initiative aims to maintain momentum after screenings, reinforce positive health behaviors, and combine clinical expertise with accessible digital tools for a more consistent approach to preventive health.
HCA Healthcare (HCA): 12 Best Value Stocks to Buy Right Now
HCA Healthcare (HCA) is featured as a top value stock, following the announcement of successful research in the New England Journal of Medicine on a CRISPR-based gene-editing therapy for sickle cell disease and beta thalassemia. This therapy, exa-cel, demonstrated efficacy in young children, leading to transfusion independence or freedom from severe vaso-occlusive crises. HCA Healthcare's Sarah Cannon Transplant and Cellular Therapy Network is expanding access to these FDA-approved gene-editing therapies at its children's hospitals.
VivaScore partners with HCA Healthcare UK to extend the impact of health screening through cutting-edge digital platform
VivaScore has partnered with HCA Healthcare UK to enhance health screening engagement through a new digital platform. This collaboration offers patients 12 months of complimentary access to VivaScore's platform, providing remote digital health check-ins and data-driven insights between clinical appointments. The initiative aims to reinforce positive health behaviors and support a consistent approach to preventative care, combining clinical expertise with accessible digital tools.
Select Medical Holdings Corporation Acquired by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS
Select Medical (NYSE: SEM) has completed its acquisition by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe for $16.50 per share, valuing the company at $3.9 billion. This price represents an 18% premium to the unaffected share price and a 25% premium to the 90-day volume-weighted average price as of November 24, 2025. Effective July 1, 2026, Select Medical will be delisted from the NYSE, with current leadership remaining in place.
HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children
HCA Healthcare announced new research published in The New England Journal of Medicine (NEJM) showing promising results from a gene-editing therapy for children aged 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. This study builds on HCA Healthcare's pioneering work in cell and gene therapy research and evaluates exagamglogene autotemcel (exa-cel). The findings suggest the potential for earlier intervention, with all evaluated participants achieving positive outcomes such as transfusion independence or freedom from severe vaso-occlusive crises for at least 12 months.
HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children
HCA Healthcare announced the publication of new research in The New England Journal of Medicine detailing promising results from a CRISPR-based gene-editing therapy for severe sickle cell disease and transfusion-dependent beta thalassemia in children aged 5-11. The study, led by Dr. Haydar Frangoul and conducted in collaboration with Sarah Cannon Research Institute, highlights the potential for earlier intervention to prevent cumulative injury. This research builds on HCA Healthcare's leadership in cell and gene therapy, with plans to expand access to these FDA-approved treatments.
